vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and 60 DEGREES PHARMACEUTICALS, INC. (SXTP). Click either name above to swap in a different company.
Solowin Holdings, Ltd. is the larger business by last-quarter revenue ($410.0K vs $303.4K, roughly 1.4× 60 DEGREES PHARMACEUTICALS, INC.). Solowin Holdings, Ltd. produced more free cash flow last quarter ($-1.6M vs $-1.8M).
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
AXG vs SXTP — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $303.4K |
| Net Profit | — | $-1.4M |
| Gross Margin | — | 60.2% |
| Operating Margin | -34.1% | -632.0% |
| Net Margin | — | -474.2% |
| Revenue YoY | — | 25.6% |
| Net Profit YoY | — | 29.7% |
| EPS (diluted) | — | $-8.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $303.4K | ||
| Q3 25 | — | $437.6K | ||
| Q2 25 | — | $100.9K | ||
| Q1 25 | — | $163.6K | ||
| Q4 24 | — | $241.6K | ||
| Q3 24 | $410.0K | $135.3K | ||
| Q2 24 | — | $125.0K | ||
| Q1 24 | — | $105.7K |
| Q4 25 | — | $-1.4M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | $-1.9M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | — | $-2.2M | ||
| Q2 24 | — | $-4.2M | ||
| Q1 24 | — | $430.5K |
| Q4 25 | — | 60.2% | ||
| Q3 25 | — | -22.9% | ||
| Q2 25 | — | 50.4% | ||
| Q1 25 | — | 55.2% | ||
| Q4 24 | — | 51.1% | ||
| Q3 24 | — | 17.4% | ||
| Q2 24 | — | 28.3% | ||
| Q1 24 | — | 38.1% |
| Q4 25 | — | -632.0% | ||
| Q3 25 | — | -531.4% | ||
| Q2 25 | — | -1590.0% | ||
| Q1 25 | — | -1168.4% | ||
| Q4 24 | — | -854.7% | ||
| Q3 24 | -34.1% | -1566.0% | ||
| Q2 24 | — | -3351.8% | ||
| Q1 24 | — | -1270.4% |
| Q4 25 | — | -474.2% | ||
| Q3 25 | — | -529.3% | ||
| Q2 25 | — | -1717.7% | ||
| Q1 25 | — | -1147.4% | ||
| Q4 24 | — | -846.3% | ||
| Q3 24 | — | -1596.4% | ||
| Q2 24 | — | -3339.0% | ||
| Q1 24 | — | 407.4% |
| Q4 25 | — | $-8.26 | ||
| Q3 25 | — | $-0.66 | ||
| Q2 25 | — | $-1.25 | ||
| Q1 25 | — | $-1.56 | ||
| Q4 24 | — | $-51.96 | ||
| Q3 24 | — | $-2.92 | ||
| Q2 24 | — | $-21.12 | ||
| Q1 24 | — | $1.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $2.8M |
| Total DebtLower is stronger | — | $150.0K |
| Stockholders' EquityBook value | $6.0M | $3.5M |
| Total Assets | $13.1M | $5.4M |
| Debt / EquityLower = less leverage | — | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.8M | ||
| Q3 25 | — | $4.1M | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | $2.5M | $5.0M | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | — |
| Q4 25 | — | $150.0K | ||
| Q3 25 | — | $150.0K | ||
| Q2 25 | — | $150.0K | ||
| Q1 25 | — | $150.0K | ||
| Q4 24 | — | $150.0K | ||
| Q3 24 | — | $150.0K | ||
| Q2 24 | — | $150.0K | ||
| Q1 24 | — | $150.0K |
| Q4 25 | — | $3.5M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | — | $2.4M | ||
| Q1 25 | — | $4.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | $6.0M | $6.0M | ||
| Q2 24 | — | $3.0M | ||
| Q1 24 | — | $7.2M |
| Q4 25 | — | $5.4M | ||
| Q3 25 | — | $6.7M | ||
| Q2 25 | — | $4.2M | ||
| Q1 25 | — | $6.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $13.1M | $7.4M | ||
| Q2 24 | — | $4.3M | ||
| Q1 24 | — | $8.4M |
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.03× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-1.7M |
| Free Cash FlowOCF − Capex | $-1.6M | $-1.8M |
| FCF MarginFCF / Revenue | -392.9% | -584.2% |
| Capex IntensityCapex / Revenue | 4.4% | 26.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-7.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.6M | ||
| Q3 24 | $-1.6M | $-1.7M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.6M | $-1.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -584.2% | ||
| Q3 25 | — | -484.2% | ||
| Q2 25 | — | -1483.6% | ||
| Q1 25 | — | -978.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -392.9% | -1252.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 26.3% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 46.9% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.4% | 10.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -2.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
